Acellera and Chemotargets collaborate on AI and physics based drug discovery
Published on March 16, 2022
In March 2022, Acellera and Chemotargets announced a collaboration combining AI and physics based methods for drug discovery research.
Acellera contributed molecular simulation, machine learning and software engineering. Chemotargets contributed predictive pharmacology, safety and chemical design methods. The collaboration was structured to apply those complementary capabilities to defined research projects.
The work is part of Acellera's history of testing its software on real molecular questions. Today, organisations can start that relationship with a bounded study on their own compounds, with the question and evaluation metrics agreed before work begins.
See Acellera benchmark studies or discuss a funded research collaboration.
About Acellera
Acellera is a software company founded in 2006. It builds molecular simulation, molecular physics and AI applications for drug discovery. Its products include PlayMolecule AI, QuantumBind Lab and ACEMD Toolkit.